<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01151215</url>
  </required_header>
  <id_info>
    <org_study_id>D0102C00004</org_study_id>
    <nct_id>NCT01151215</nct_id>
  </id_info>
  <brief_title>Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer</brief_title>
  <acronym>MINT</acronym>
  <official_title>A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of AZD8931 In Combination With Anastrozole, Compared to Anastrozole Alone, in Post Menopausal Women With Hormone Receptor Positive, Endocrine Therapy Naive, Locally Advanced or Metastatic Breast Cancer (MINT).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to compare progression free survival in patients treated
      with AZD8931 given in combination with anastrozole versus anastrozole alone. The secondary
      objective is to investigate the safety and tolerability of AZD8931 given in combination with
      anastrozole.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Futility
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival as Evaluated by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1</measure>
    <time_frame>Tumour assessment by RECIST 1.1 every 12 weeks until data cut-off at 31 August 2012</time_frame>
    <description>Time from the date of randomization until the date of objective disease progression (as per RECIST 1.1) or the date of death (by any cause in the absence of progression). Disease progression is defined using RECIST 1.1 as &gt;=20% increase in the sum of longest diameters of target lesions and an absolute increase of &gt;=5mm, taking as reference the smallest sum of longest diameters of target lesions since study start, or unequivocal progression in non-target lesions, or appearance of any new lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the Overall Survival in Patients Treated With AZD8931 in Combination With Anastrozole Versus Anastrozole Alone</measure>
    <time_frame>Following progression, patients were contacted at 12 weekly intervals until data cut-off at 31 August 2012 to determine survival status</time_frame>
    <description>Time from the date of randomization to the date of death (by any cause)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">482</enrollment>
  <condition>Neoplasms</condition>
  <condition>Breast Neoplasms</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD8931 40mg (bd) plus anastrozole 1mg (od)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD8931 20mg (bd) plus anastrozole 1mg (od)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (bd) plus anastrozole 1mg (od)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD8931</intervention_name>
    <description>Tablet, oral, bd</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anastrozole</intervention_name>
    <description>Tablet, oral, od</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Arimidex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet, oral</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients that have locally advanced or metastatic breast cancer. Lesions should not be
             amenable to surgery or radiation of curative intent

          -  Hormone therapy-naive

          -  Estimated life expectancy of more than 12 weeks

        Exclusion Criteria:

          -  Last dose of prior anti-cancer therapy received within 14 days (or longer if required)

          -  Any eye injury or corneal surgery within 3 months prior to receiving first dose of
             study drug.

          -  Currently receiving (and unwilling to discontinue) oestrogen replacement therapy.
             (last dose &lt;7 days prior to randomisation)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Serban Ghiorghiu, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Johnston, MA, PhD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Royal Marsden Hospital, London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goiânia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ijuí</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 2</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 4</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trivandrum</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vellore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Niigata-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ota-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durango</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Juchitan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Merida</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Callao</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Piura</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iloilo City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lipa City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pasay City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elbląg</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kuzmolovsky</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Songkla</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Surrey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wythenshawe, Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>India</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Colombia</country>
  </removed_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2010</study_first_submitted>
  <study_first_submitted_qc>June 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2010</study_first_posted>
  <results_first_submitted>January 29, 2014</results_first_submitted>
  <results_first_submitted_qc>April 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 8, 2014</results_first_posted>
  <last_update_submitted>July 15, 2014</last_update_submitted>
  <last_update_submitted_qc>July 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>tumour</keyword>
  <keyword>breast cancer</keyword>
  <keyword>metastatic</keyword>
  <keyword>secondary</keyword>
  <keyword>locally advanced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>482 patients were enrolled into the study, of these, 123 patients failed screening and 359 patients were randomized, 120 to AZD8931 40mg(bd) plus anastrozole 1mg (od), 118 to AZD8931 20mg(bd) plus anastrozole 1mg (od) and 121 to placebo(bd) plus anastrozole 1mg(od)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AZD8931 40mg + Anastrozole 1mg</title>
          <description>AZD8931 40mg (bd) plus anastrozole 1mg (od)</description>
        </group>
        <group group_id="P2">
          <title>AZD8931 20mg + Anastrozole 1mg</title>
          <description>AZD8931 20mg (bd) plus anastrozole 1mg (od)</description>
        </group>
        <group group_id="P3">
          <title>Placebo + Anastrozole 1mg</title>
          <description>Placebo (bd) plus anastrozole 1mg (od)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="118"/>
                <participants group_id="P3" count="121"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100">This is number of patients who were continuing at cut off (ie not withdrawn)</participants>
                <participants group_id="P2" count="95">This is number of patients who were continuing at cut off (ie not withdrawn)</participants>
                <participants group_id="P3" count="102">This is number of patients who were continuing at cut off (ie not withdrawn)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Worsening of condition under study</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Safety as judged by the investigator</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZD8931 40mg + Anastrozole 1mg</title>
          <description>AZD8931 40mg (bd) plus anastrozole 1mg (od)</description>
        </group>
        <group group_id="B2">
          <title>AZD8931 20mg + Anastrozole 1mg</title>
          <description>AZD8931 20mg (bd) plus anastrozole 1mg (od)</description>
        </group>
        <group group_id="B3">
          <title>Placebo + Anastrozole 1mg</title>
          <description>Placebo (bd) plus anastrozole 1mg (od)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="120"/>
            <count group_id="B2" value="118"/>
            <count group_id="B3" value="121"/>
            <count group_id="B4" value="359"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.4" spread="10.69"/>
                    <measurement group_id="B2" value="62.0" spread="11.23"/>
                    <measurement group_id="B3" value="60.5" spread="10.29"/>
                    <measurement group_id="B4" value="61.0" spread="10.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <description>Female only</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="121"/>
                    <measurement group_id="B4" value="359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ethnicity: Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ethnicity: Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ethnicity: African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ethnicity: Asian (other than Chinese/Japanese)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ethnicity: Chinese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ethnicity: Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ethnicity: Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ethnicity: Not applicable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Race: American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race: Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race: Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race: Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race: White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race: Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Study Stratification: Disease Classification</title>
          <description>Study was stratified by locally advanced / metastatic disease</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Locally advanced</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metastatic disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival as Evaluated by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1</title>
        <description>Time from the date of randomization until the date of objective disease progression (as per RECIST 1.1) or the date of death (by any cause in the absence of progression). Disease progression is defined using RECIST 1.1 as &gt;=20% increase in the sum of longest diameters of target lesions and an absolute increase of &gt;=5mm, taking as reference the smallest sum of longest diameters of target lesions since study start, or unequivocal progression in non-target lesions, or appearance of any new lesions.</description>
        <time_frame>Tumour assessment by RECIST 1.1 every 12 weeks until data cut-off at 31 August 2012</time_frame>
        <population>Full Analysis Set (all participants randomized, irrespective of whether treatment was received). Participants are analysed according to the treatment group they were randomized to.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8931 40mg + Anastrozole 1mg</title>
            <description>AZD8931 40mg (bd) plus anastrozole 1mg (od)</description>
          </group>
          <group group_id="O2">
            <title>AZD8931 20mg + Anastrozole 1mg</title>
            <description>AZD8931 20mg (bd) plus anastrozole 1mg (od)</description>
          </group>
          <group group_id="O3">
            <title>Placebo + Anastrozole 1mg</title>
            <description>Placebo (bd) plus anastrozole 1mg (od)</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival as Evaluated by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1</title>
          <description>Time from the date of randomization until the date of objective disease progression (as per RECIST 1.1) or the date of death (by any cause in the absence of progression). Disease progression is defined using RECIST 1.1 as &gt;=20% increase in the sum of longest diameters of target lesions and an absolute increase of &gt;=5mm, taking as reference the smallest sum of longest diameters of target lesions since study start, or unequivocal progression in non-target lesions, or appearance of any new lesions.</description>
          <population>Full Analysis Set (all participants randomized, irrespective of whether treatment was received). Participants are analysed according to the treatment group they were randomized to.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="121"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Events</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" lower_limit="5.5" upper_limit="22.1"/>
                    <measurement group_id="O2" value="10.9" lower_limit="5.4">Upper limit of inter-quartile range is not calculable</measurement>
                    <measurement group_id="O3" value="14.0" lower_limit="6.7" upper_limit="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>345 patients were to be randomised to observe at least 233 progression events, based on HR=0.60, 90% power, 2-sided 5% significant level and a median of 9 months for the placebo arm. An interim analysis with futility boundary was introduced based on an IDMC recommendation.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.485</p_value>
            <p_value_desc>Statistical significance threshold at this interim analysis was 5%</p_value_desc>
            <method>Log Rank</method>
            <method_desc>The log rank test was stratified for the IVRS stratification factor of disease classification (locally advanced / metastatic disease)</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.75</ci_upper_limit>
            <estimate_desc>The Hazard Ratio is for AZD8931 40mg + anastrozole 1mg / Placebo + anastrozole 1mg, ie a hazard ratio &lt;1 favours AZD8931 40mg + anastrozole 1mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>345 patients were to be randomised to observe at least 233 progression events, based on HR=0.6, 90% power, 2-sided 5% significant level and a median of 9 months for the placebo arm. An interim analysis with futility boundary was introduced based on an IDMC recommendation.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.135</p_value>
            <method>Log Rank</method>
            <method_desc>The log rank test was stratified for the IVRS stratification factor of disease classification (locally advanced / metastatic disease)</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>2.06</ci_upper_limit>
            <estimate_desc>The Hazard ratio is for AZD8931 20mg + anastrozole 1mg / Placebo + anastrozole 1mg, ie a hazard ratio &lt; 1 favours AZD8931 20mg + anastrozole 1mg</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare the Overall Survival in Patients Treated With AZD8931 in Combination With Anastrozole Versus Anastrozole Alone</title>
        <description>Time from the date of randomization to the date of death (by any cause)</description>
        <time_frame>Following progression, patients were contacted at 12 weekly intervals until data cut-off at 31 August 2012 to determine survival status</time_frame>
        <population>Full Analysis Set (all participants randomized, irrespective of whether treatment was received). Participants are analysed according to the treatment group they were randomized to.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8931 40mg + Anastrozole 1mg</title>
            <description>AZD8931 40mg (bd) plus anastrozole 1mg (od)</description>
          </group>
          <group group_id="O2">
            <title>AZD8931 20mg + Anastrozole 1mg</title>
            <description>AZD8931 20mg (bd) plus anastrozole 1mg (od)</description>
          </group>
          <group group_id="O3">
            <title>Placebo + Anastrozole 1mg</title>
            <description>Placebo (bd) plus anastrozole 1mg (od)</description>
          </group>
        </group_list>
        <measure>
          <title>Compare the Overall Survival in Patients Treated With AZD8931 in Combination With Anastrozole Versus Anastrozole Alone</title>
          <description>Time from the date of randomization to the date of death (by any cause)</description>
          <population>Full Analysis Set (all participants randomized, irrespective of whether treatment was received). Participants are analysed according to the treatment group they were randomized to.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="121"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Events</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="4.6" upper_limit="14.3"/>
                    <measurement group_id="O2" value="8.3" lower_limit="4.7" upper_limit="14.0"/>
                    <measurement group_id="O3" value="7.9" lower_limit="4.6" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AZD8931 20mg</title>
        </group>
        <group group_id="E2">
          <title>AZD8931 40mg</title>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>COR PULMONALE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>GASTRIC HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL VARICES HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>GAIT DISTURBANCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERBILIRUBINAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>EJECTION FRACTION DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>HYPERCALCAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>PATHOLOGICAL FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBELLAR INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>COMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>MONOPARESIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>TUBULOINTERSTITIAL NEPHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BREAST HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>BRONCHOSPASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>PLEURITIC PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATITIS ACNEIFORM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 15</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="115" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="99" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="118"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>BLEPHARITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>DRY EYE</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="118"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>EYE PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>VITREOUS FLOATERS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="118"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>EYE IRRITATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>EYE PRURITUS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="118"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>OCULAR HYPERAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>TOOTHACHE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="118"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="118"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="118"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="70" subjects_affected="46" subjects_at_risk="118"/>
                <counts group_id="E2" events="103" subjects_affected="61" subjects_at_risk="120"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>MOUTH ULCERATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="118"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="120"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="118"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>TONGUE ULCERATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="118"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="120"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>MUCOSAL DRYNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="118"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E3" events="11" subjects_affected="5" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>SPINAL PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>SWELLING</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>XEROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>OEDEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="118"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>FEELING COLD</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>MUCOSAL INFLAMMATION</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="118"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>PARONYCHIA</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="118"/>
                <counts group_id="E2" events="26" subjects_affected="22" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>BREAST INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>FUNGAL INFECTION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>FOLLICULITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>FURUNCLE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>LOCALISED INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>NAIL INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>ONYCHOMYCOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>RASH PUSTULAR</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="118"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="118"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="118"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="120"/>
                <counts group_id="E3" events="15" subjects_affected="10" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>EJECTION FRACTION DECREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>WEIGHT INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>BLOOD ALKALINE PHOSPHATASE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM QT PROLONGED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>HYPERCALCAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="118"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="120"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>HYPOALBUMINAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="118"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="118"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E3" events="27" subjects_affected="23" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="118"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="118"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>TUMOUR HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="120"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SENSORY NEUROPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>AGEUSIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="118"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E3" events="23" subjects_affected="18" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>LETHARGY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>MOOD SWINGS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E2" events="11" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>LEUKOCYTURIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>PROTEINURIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>VULVOVAGINAL DRYNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>BREAST PAIN</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E3" events="15" subjects_affected="6" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>VAGINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PRODUCTIVE COUGH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="118"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>NASAL DRYNESS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>BRONCHOSPASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>DYSPHONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>NASAL INFLAMMATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>RHINORRHOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BLISTER</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>NAIL DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="118"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="118"/>
                <counts group_id="E2" events="32" subjects_affected="30" subjects_at_risk="120"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>HYPERHIDROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>NAIL RIDGING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>ONYCHOMADESIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>PAPULE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>RASH ERYTHEMATOUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>SKIN EXFOLIATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>ACNE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>DERMATITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>DERMATITIS ACNEIFORM</sub_title>
                <counts group_id="E1" events="23" subjects_affected="19" subjects_at_risk="118"/>
                <counts group_id="E2" events="37" subjects_affected="31" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E3" events="15" subjects_affected="3" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>NAIL DYSTROPHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="118"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="42" subjects_affected="38" subjects_at_risk="118"/>
                <counts group_id="E2" events="78" subjects_affected="56" subjects_at_risk="120"/>
                <counts group_id="E3" events="20" subjects_affected="15" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>RASH MACULO-PAPULAR</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="118"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>RASH PAPULAR</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>LYMPHOEDEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>HOT FLUSH</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="118"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The final analysis for this study is the analysis that was sent to the study's IDMC, based on a data cut-off of 31 August 2012. At the data cut-off point the data was cleaned, but 9 adverse events were not coded. These events are not included here.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Serban Ghiorghiu</name_or_title>
      <organization>Astrazeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

